ARS Pharmaceuticals, Inc. (SPRY) Institutional Ownership & Insider Trading

206 institutions reported holding ARS Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 5 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

SPRYARS Pharmaceuticals, Inc.Follow SPRY — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 400.8M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 17 Nov, in 24 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

206 institutions held 91.2% of the shares. Across filers that reported both quarters, shares held changed -3.8%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	206	91	-3.8%	69	32	52	28
Mar 26	200	93	+4.8%	54	32	51	23
Dec 25	188	89	+5.9%	54	26	54	28
Sep 25	187	84	-1.2%	65	36	40	40
Jun 25	186	85	+11.2%	77	26	43	18
Mar 25	183	76	+6.7%	57	36	49	20
Dec 24	164	71	+14.4%	53	24	41	15
Sep 24	150	64	+2.1%	55	45	20	11

ARS Pharmaceuticals, Inc. — questions

Who owns ARS Pharmaceuticals, Inc. stock?: 206 institutions reported ARS Pharmaceuticals, Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: RA CAPITAL MANAGEMENT, L.P. (10.9%), Rubric Capital Management LP (8.6%), ORBIMED ADVISORS LLC (8.3%).
Are ARS Pharmaceuticals, Inc. insiders buying or selling?: 5 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from ARS Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.